Professor Peter Selby CBE, DSc, MD, FMedSci, FRCR, FRCP

Professor Peter Selby CBE, DSc, MD, FMedSci, FRCR, FRCP

Professor of Cancer Medicine
President of the Association of Cancer Physicians and the European Cancer Concord

0113 2065668

Summary: I am Professor of Cancer Medicine at the University of Leeds and a Consultant Physician at St James’s University Hospital specialising in medical oncology.

Location: Cancer Research Building



Peter Selby is a consultant physician at St James’s University Hospital, the St James’s Institute of Oncology and Professor of Cancer Medicine at the University of Leeds.  He has worked in cancer research and cancer care since 1976.  After completing a Natural Sciences degree at the University of Cambridge in 1971, he undertook undergraduate medical training at King’s College Hospital in London and then medical and oncological training posts in Kings College Hospital, University College Hospital and the Royal Marsden Hospital in London and in the Princess Margaret Hospital and Ontario Cancer Institute in Toronto.  He was a clinical research fellow at the Institute for Cancer Research and Royal Marsden and became a Consultant and Senior Lecturer there in 1984. 

His clinical interests have covered a wide range of cancer treatments and tumour sites, most recently urological cancers and cancers of teenagers and young adults.  His research programmes have included high dose chemotherapy with bone marrow/stem cell transplants, antiviral treatments, combination chemotherapies, biological therapies and biomarkers, psychosocial oncology and psychometrics and clinical trials.  His current research programmes are in biomarker discovery and evaluation funded as a PI mainly by the National Institute for Health Research with an NIHR Applied Programme and NIHR Diagnostic Evidence Cooperative and in biological therapy funded by the European Research Council with an Advanced Award.

Peter was Head of Oncology and Cancer Research in Leeds (1988-2010), was Director of the Leeds Biomedical and Health Research Centre (2008-2012) which linked basic science with translational and clinical research in Leeds and was Director of the Leeds Institute of Molecular Medicine (2002-2005 and 2010-2013).  From 2000-2004 he initiated and was Director of the National Cancer Research Network and from 2004-2010 he initiated and was Joint Director of the NIHR Clinical Research Network, providing support to clinical research within the NHS and delivering improvements in participation and the quality of research and services.

He was appointed Fellow of the Academy of Medical Sciences in 1998, and awarded a CBE in 2001 for services to cancer research and cancer care.  Peter  is President of the Association of Cancer Physicians (2007-) and won the Pfizer Excellence in Oncology Lifetime Achievement award in 2007.  He is an Honorary Life member of the British Psychosocial Oncology Society and remains a co-investigator on patient reported outcome research into prostate cancer and chemotherapy toxicity.  In 2010 he was appointed a Senior Investigator of the National Institute for Health Research.  In 2011 he was awarded a DSc. 

As Director/Lead Clinician of the NHS Leeds Cancer Centre (1997-2003) he organised specialised multidisciplinary care for cancer patients and led the development of excellent facilities for patients.  More recently (2013) he helped to initiate an Integrated Cancer Service to address the need for better access to care and address inequalities.  He was Consultant Advisor on Cancer Services to the Chief Medical Officer in England (Sir Kenneth Calman) (1993-2000) and is President and Chief Executive of the European Cancer Concord (2014-).  In both latter roles he sought to develop and implement evidence-based plans to improve outcomes for cancer patients and tackle cancer inequalities.  Peter is a Trustee of Cancer Research UK (2012-), Chairman of the Cancer Research UK Public Policy Advisory Group and a member of the Cancer Research UK Research Strategy Committee.

1) Stem and Clonogenic Cell Studies and High Dose Chemotherapy

Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole body irradiation.  Selby P, Thomas JM and Monagham P, et al.  British Journal of Cancer 1980; 41: 52-61.

Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy.  Selby P, Courtenay VD, McElwain TJ, et al.  British Journal of Cancer 1980; 42: 438-447.

Clonogenic cell survival in cryopreserved human tumor cells.  Selby P, Steel GG.  British Journal of Cancer 1981; 43: 143-148. 

Use of the agar diffusion chamber for the exposure of human tumor cells to drugs.  Selby P, Steel GG.  Cancer Research 1982; 42: 4758 4762.

A critical appraisal of the human tumor stem cell assay.  Selby P, Buick RN, Tannock I.  New England Journal of Medicine 1983; 308: 129 134.

High dose treatment with melphalan and methylprednisolone for multiple myeloma.  Selby P, Ayliffe M, Behrens J, et al.  Monoclonal Gammopathies: Clinical Significance and Basic Mechanisms.  Eds Van Dam B, et al 1985; 151 154.

Multiple myeloma treated with high dose intravenous melphalan.  Selby P, McElwain, TJ, Nandi AC, et al. British Journal of Haematology 1987; 66: 55 62. 

The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital Studies.  Selby P, Zulian G, Forgeson D, et al.  Haematological Oncology 1988; 6: 173-179. 

Intensive treatment of multiple myeloma and criteria for complete remission.  Gore M E, Selby P, Viner C, et al.  The Lancet 1989; 2: 879-882. 
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Child JA, Morgan G, Davies F, Owen R, Bell S, Hawkins K, Brown J, Drayson M, Selby P. New England Journal of Medicine 2003 8; 348: 19, 1875-83.

2) New Drugs to Reduce Toxicity

Parenteral acyclovir therapy for herpes virus infections in man.  Selby P, Powles RL, Jameson B, et al.  The Lancet 1979; ii: 1267-1270.

Amino(hydroxyethoxymethyl)purine: A new well absorbed prodrug of acyclovir.  Selby P, Powles R, Blake S, et al.  The Lancet 1984; ii: 1428-1430.

Treatment of cytomegalovirus pneumonitis after bone marrow transplantation with 9 [2 Hydroxy 1 (hydroxymethyl) Ethoxymethyl] guanine (letter).  Selby P, Powles RL, Jameson B, et al.  The Lancet 1986; i: 1377 1378.

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.  Selby P, Powles RL, Easton D, et al.  British Journal of Cancer 1989; 59: 434-438. 

Ondansetron - a new safe and effective antiemetic in patients receiving high-dose melphalan.  Viner CV, Selby P, Zulian GB, et al.  Cancer Chemotherapy Pharmacology 1990; 25: 449-453. 

3) Psychosocial Oncology and Patient Reported Outcome Measures

The development of a method for assessing the quality of life of cancer patients.  Selby P, Chapman JW, Etazadi Amoli J, et al.  British Journal of Cancer 1984; 50: 13 22.

Measurement of the clinical status of patients with breast cancer: evidence for the validity of self assessment with linear analogue scales.  Boyd NF, Selby P, Sutherland HJ, et al.  Journal of Clinical Epidemiology 1988; 41: 3, 243 250. 

Assessing quality of life in cancer patients.  Maguire P, Selby P.  British Journal of Cancer 1989; 60: 437-440. 

A method for assessing the quality of life of cancer patients: replication of the factor structure.  Bliss JM, Selby P, Robertson B, et al.  British Journal of Cancer 1992; 65: 961-966. 
Automated collection of quality of life data: a comparison of paper and computer touchscreen questionnaires.  Velikova G, Wright E, Smith A, Cull A, Gould A, Forman D, Perren T, Stead M, Brown J, Selby P.  Journal of Clinical Oncology 1999; 17: 3, 998-1007.

Self-reported quality of life (QL) of individual cancer patients - concordance of results with disease course and medical records.  Velikova G, Wright P, Smith A, Stark D, Brown J, Selby P.  Journal of Clinical Oncology 2001; 19: 7, 2064-2073.

Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study.  Stead M, Fallowfield L, Brown J, Selby P.  British Medical Journal 2001; 323: 836-7.

Detecting social problems in cancer patients.  Wright P, Selby P, Gould A, Cull A.  Psycho-Oncology 2001; 10: 242-250.

Anxiety disorders in cancer patients: their nature, associations and relation to quality of life.  Stark D, Kiely M, Smith A, Velikova G, House A, Selby P.  Journal of Clinical Oncology 2002; 20: 3137-3148.

Feasibility and compliance of automated measurement of quality of life in oncology practice.  Wright EP, Selby P, Gillibrand A, Smith A, Velikova G, Crawford M, Perren T, Gould A, Cull A.  Journal of Clinical Oncology 2003; 21: 2; 374-82.

Measuring quality of life routine oncology practice – improves communication and patient well-being: a randomised controlled trial.  Velikova G, Booth L, Smith AB, Brown P, Lynch P, Brown J, Selby P.  Journal of Clinical Oncology 2004; 22: 4, 714-724. 

Development and evaluation of an instrument to assess social difficulties in routine oncology practice.    Wright EP, Kiely M, Johnston C, Smith AB, Cull A, Selby PJ.  Quality of Life Research 2005;14:373-86.

Measuring social difficulties in routine patient-centred assessment: a Rasch analysis of the social difficulties inventory. Smith AB, Wright P, Selby P, Velikova G.  Qual Life Res 2007; 16(5):823-831.

Measurement and interpretation of social distress using the Social Difficulties Inventory (SDI). Wright E, Marshall L, Smith A, Velikova G, Selby P.  European Journal of Cancer 2008; Jul; 44(11):1529-35.

Impact of routine measurement of patient-reported outcomes on patient-doctor communication in oncology – continued effects over time.  Takeuchi EE, Keding A, Awad N, Hofmann U, Campbell L, Selby P, Brown JM and Velikova G.  J Clin Oncol. 2011 Jul 20;29(21):2910-7.

4) Biotherapy

Tumour necrosis factor in man: clinical and biological observations.  Selby P, Hobbs S, Viner C, et al.  British Journal of Cancer 1987; 56: 803-808. 
The impact of interleukin-2 on survival in renal cancer: A multivariate analysis.  Jones M, Selby P, Franks C, et al.  Cancer Biotherapy 1993; 8: 4, 275-288. 

Interferon alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial.  MRC Renal Cancer Working Party 1998.  Lancet 1999; 353: 14-17.

Purging Metastases in Lymphoid Organs Using a Combination of Antigen-non Specific Adoptive T Cell Therapy, Oncolytic Virotherapy, and Immunotherapy.  Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz R, Thompson J, Ryno P, Barber G, Chester J, Selby P, Harrington K, Melcher A, Vile R. Nature Medicine 2008; Jan;14(1):37-44.

An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ.  Eur J Cancer. 2008; Jan;44(2):216-23.

Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: A phase I trial.  Schmidt H, Brown J, Mouritzen U, Selby P, Fode K, Hal Mollerup D, Geertsen P.  Clin Cancer Res 2010; 16: 21, 5312-9.
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.  Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R.  Nature Medicine 2011; 17: 854–859.
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.  Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R.  Nat Biotechnol. 2012 Mar 18;30(4):337-43.

Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.  Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, Pandha H, Melcher A, Harrington K, Selby P, Vile R.  Nat Med. 2013 Dec;19(12):1625-31

The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site.  Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R.  Mol Ther. 2014 Jul 25.

5) Biomarkers

The detection of melanoma cells in the peripheral blood using reverse transcriptase-polymerase chain reactions.  Smith B, Selby P, Pittman K, et al.  The Lancet 1991; 338: 1227-1229. 

Neuroblastoma cell detection in peripheral blood by reverse transcriptase-polymerase chain reaction (RT-PCR).  Burchill S, Bradbury M, Smith B, Lewis I, Selby P.  International Journal of Cancer 1994; 57: 671-675. 

Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction.  Burchill S, Bradbury M, Pittman K, Southgate J, Smith B, Selby P.  British Journal of Cancer 1995; 71: 278-281. 

Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood.  Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, Selby P.  Annals of Oncology 1996; 7: 297-301. 

Proteomics - new perspectives, new biological opportunities.  Banks R, Dunn M, Hochstrasser D, Sanchez J, Blackstock W, Pappin D, Selby P.  Lancet 2000; 356: 1749-1756.

Commentary - Clinical proteomics - insights into pathologies and benefits for patients.  Banks R, Selby P.  Lancet 2003; 362:415-416.

The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers from patients with metastatic prostate cancer.  Patel K, Whelan PJ, Prescott S, Brownhill SC, Johnston CF, Selby PJ, Burchill SA (2004). Clin Cancer Res 10, 7511-7519.

Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene  alterations and relationship with clinical variables in sporadic renal cancer.  Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, Knowles M, Selby PJ.  Cancer Res. 2006 Feb 15;66(4):2000-11.

Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.  Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.  Clin Cancer Res 2007; Dec 15;13(24):7370-9.

Prognostic factors in renal cell carcinoma: Association of pre-operative sodium concentration with survival. Vasudev NS, Brown  J E, Brown SR, Rafiq R, Morgan R, Patel PM, O'Donnell D, Harnden P, Rogers M, Cocks K, Anderson K, Paul A, Eardley I, Selby P, Banks R.  Clinical Cancer Research 2008;14(6):1775-81.

Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.  Purdue MP, Johansson M, Banks RE, Selby PJ, Harnden P, Lathrop M, Brennan P et al.  Nat Genet. 2011 Jan;43(1):60-5.

A genome-wide association study identifies a novel susceptibility locus for renal cell  carcinoma on 12p11.23.  Wu X, Scelo G, Banks RE, Selby PJ, Harnden P, Brennan P, Chanock SJ et al.  Hum Mol Genet. 2012 Jan 15;21(2):456-62. 
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Welberry Smith MP, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ, Lewington AJ, Banks RE. Kidney Int. 2013 Dec;84(6):1214-25.

6) Improving Cancer Care

Benefits from specialised cancer care.  Selby P, Gillis C, Haward R.  The Lancet 1996; 348: 313-18. 

Cancer clinical outcomes for minority ethnic groups.  Selby P.  British Journal of Cancer 1996; 74: Supplement XXIX, S54-S60. 

Cancer in old age - is it adequately investigated and treated?  Turner N, Haward R, Mulley G, Selby P.  British Medical Journal 1999; 319: 309-12.

Breast cancer outcomes in South Asian population of West Yorkshire.  Velikova G, Booth L, Johnston C, Forman D, Selby P.  British Journal of Cancer 2004; 90: 1926-32.

Strengthening clinical cancer research in the United Kingdom.  Stead M, Cameron D, Lester N, Parmar M, Haward R, Kaplan R, Maughan T, Wilson R, Campbell H, Hamilton R, Stewart D, O'Toole L, Kerr D, Potts V, Moser R, Darbyshire J, Selby P.  Br J Cancer 2011 May 10;104(10):1529-34.
The impact of the process of clinical research on health service outcomes. Selby P, Autier P.  Ann Oncol. 2011 Nov;22 Suppl 7:vii5-vii9.

Research-intensive cancer care in the NHS in the UK.  Cameron D, Stead M, Lester N, Parmar M, Haward R, Maughan T, Wilson R, Spaull A, Campbell H, Hamilton R, Stewart D, O'Toole L, Kerr D, Potts V, Moser R, Cooper M, Poole K, Darbyshire J, Kaplan R, Seymour M, Selby P.   Ann Oncol. 2011 Nov;22 Suppl 7:vii29-vii35.

Extending the clinical research network approach to all of healthcare.  Darbyshire J, Sitzia J, Cameron D, Ford G, Littlewood S, Kaplan R, Johnston D, Matthews D, Holloway J, Chaturvedi N, Morgan C, Riley A, Rossor M, Kotting P, McKeith I, Smye S, Gower J, Brown V, Smyth R, Poustie V, van't Hoff W, Wallace P, Ellis T, Wykes T, Burns S, Rosenberg W, Lester N, Stead M, Potts V, Johns C, Campbell H, Hamilton R, Sheffield J, Selby P.  Ann Oncol. 2011 Nov;22 Suppl 7:vii36-vii43.

Patient and public involvement.  Stewart D, Wilson R, Selby P, Darbyshire J.  Ann Oncol. 2011 Nov;22 Suppl 7:vii54-vii56.

Addressing cancer disparities in Europe: a multifaceted problem that requires interdisciplinary solutions.  Oncologist.  Duffy S, Richards M, Selby P, Lawler M.  2013;18(12):e29-30.

Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours.  Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ.  BJU Int. 2014 Mar;113(3):416-28.

Ageism in cancer care.  Lawler M, Selby P, Aapro MS, Duffy S.  BMJ.  2014 Feb 28;348:g1614.

European Cancer Concord (ECC).  Lawler M, Le Chevalier T, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Murphy MJ, Johnston PG.  A Bill of Rights for patients with cancer in Europe. Lancet Oncol. 2014 Mar;15(3):258-60.

A catalyst for change: the European cancer Patient's Bill of Rights.  Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM,  Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P,  Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG.  Oncologist.  2014 Mar;19(3):217-24.